|
Antibody drug conjugates are created by linking a potent small molecule to a monoclonal antibody (mAb). It combines the potency of cytotoxic drugs with the high specificity of monoclonal antibody to target many oncology diseases. Due to the small molecule property, the chemical linking chemistry and different amino acid conjugation, antibody drug conjugate (ADC) exhibits a more complex and heterogeneous structure than the parent monoclonal antibody.
In this webinar, we would like to present the ADC characterization in the following four areas.
- Size exclusion chromatography (SEC):
- ADC aggregate, monomer and fragment analysis using Zenix®-C SEC-300 size exclusion chromatography. This analysis can be part of the ADC lot release and stability assays.
- Free small molecule drugs analysis after the conjugation reaction can be achieved with Zenix®-C SEC-80 (the smallest pore size 80 Å in the Sepax SEC product line).
- Volatile mass spec friendly mobile phase can be applied to determine the intact mass of ADC
- Hydrophobic interaction chromatography (HIC): ADC with cysteine conjugates drug to antibody ratio (DAR) can be monitored by Proteomix® HIC Butyl, fractions can be collected and further analyzed by other analytical methods.
- Cation exchange chromatography (CEX): ADC charge variants can be characterized by CEX.
- Reversed-phase chromatography (RP): mAb and ADC large fragments such as HC/LC, Fab/Fc and fragments from IDES digestion can be analyzed by Proteomix® RP and detected by LC/MS.
|
|
